Compare
Compugen Ltd vs Recursion Pharmaceuticals, Inc. vs Autolus Therapeutics plc vs Champions Oncology, Inc.
| Latest fiscal year | Compugen Ltd CGEN | Recursion Pharmaceuticals, Inc. RXRX | Autolus Therapeutics plc AUTL | Champions Oncology, Inc. CSBR |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2026-04-30 |
| Revenue | $72.76M | $74.68M | $75.39M | $59.42M |
| Revenue growth (YoY) | +161.1% | +26.9% | +644.9% | +4.4% |
| Gross margin | 87.3% | 5.0% (computed) | -27.8% (computed) | 48.0% (computed) |
| Operating margin | 43.1% | -867.9% | -358.9% | -1.9% |
| Net margin | 48.6% | -863.4% | -381.4% | -2.0% |
| Net income | $35.34M | -$644.76M | -$287.53M | -$1.18M |
| EPS (Diluted) | $0.38 | -$1.44 | -$1.08 | -$0.08 |
| Operating cash flow | $31.63M | -$371.81M | -$283.57M | -$4.47M |
| Free cash flow | $31.33M | -$378.28M | -$302.61M | -$5.04M |
| Cash & equivalents | $90.60M | $743.29M | $104.13M | n/a |
| Total assets | $156.57M | $1.47B | $589.07M | $26.99M |
| Total liabilities | n/a | $343.26M | $410.94M | $22.92M |
| Shareholders' equity | $102.73M | $1.13B | $178.13M | $3.94M |
| Return on year-end equity | 34.4% | -57.0% | -161.4% | -29.8% |
| Shares outstanding | 94.55M | 528.18M | n/a | 13.89M |
Revenue, most recent five fiscal years
| Fiscal year | Compugen Ltd | Recursion Pharmaceuticals, Inc. | Autolus Therapeutics plc | Champions Oncology, Inc. |
|---|---|---|---|---|
| Latest | $72.76M Ended 2025-12-31 | $74.68M Ended 2025-12-31 | $75.39M Ended 2025-12-31 | $59.42M Ended 2026-04-30 |
| 1 year earlier | $27.86M Ended 2024-12-31 | $58.84M Ended 2024-12-31 | $10.12M Ended 2024-12-31 | $56.94M Ended 2025-04-30 |
| 2 years earlier | $33.46M Ended 2023-12-31 | $44.58M Ended 2023-12-31 | $1.70M Ended 2023-12-31 | $50.16M Ended 2024-04-30 |
| 3 years earlier | $7.50M Ended 2022-12-31 | $39.84M Ended 2022-12-31 | n/a | $53.87M Ended 2023-04-30 |
| 4 years earlier | $6.00M Ended 2021-12-31 | $10.18M Ended 2021-12-31 | n/a | $49.11M Ended 2022-04-30 |